Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
NCT01540071
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class
Conditions
Castration Resistant Prostate Cancer
Interventions
DRUG:
NRX 194204
Sponsor
Io Therapeutics